ICLUSIG
Identification of Iclusig
| No description |
Google image searchProduct monograph
Active ingredient
ponatinib (ponatinib hydrochloride), 15 MG
DIN: 02437333
Dosage form(s): TABLET
Route(s) of administration: ORAL
Schedule: Prescription
Company: TAKEDA PHARMACEUTICALS U.S.A., INC.
Date: 29-JUN-2023
ATC:
- L01 — ANTINEOPLASTIC AGENTS (ATC, ATC/DDD, )
- L01E — PROTEIN KINASE INHIBITORS (ATC, ATC/DDD)
- L01EA — BCR-ABL tyrosine kinase inhibitors (ATC, ATC/DDD)
- L01EA05 — PONATINIB (ATC/DDD)
Reference brand drug: Iclusig
